Date & Time
Location
Virtual - Zoom
Registration Information
Event Overview
Mechanisms that impact the way our genomes are expressed and stabilized without changing its DNA sequence are influenced through the epigenetic character of chromatin. DNA, RNA, and histone modifications as well as chromatin structure contribute to the epigenetic mechanisms controlling gene expression, genome stability, cell fate and differentiation. Both the scientific and clinical communities recognize that epigenetic dysregulation contributes to tumorigenesis, tumor drug response and resistance with changes to the tumor microenvironment, likely leading to the currently unexplained variability in cancer survivorship. Cancer genome sequencing efforts have highlighted mutations in numerous epigenetic factors altering chromatin features, which in turn, deregulates gene expression, genome stability, replication, and cell fate. The posttranscriptional modulation of RNA (or epitranscriptomics) has emerged as another layer of epigenetic control impacting tumorigenesis. Therefore, the enzymes regulating histone and nucleic modifications serve as novel targets and provide opportunities to develop biomarkers and novel therapies. This one-day symposium will feature world-leaders in cancer epigenetics that will highlight discoveries related to epigenetic mechanisms driving tumorigenesis and novel therapeutic opportunities to better target cancer.
Event Timeline
8:45–8:50 AM: Conference Begins; Attendees Sign On
8:50–9:05 AM: Welcome & Opening Remarks - Dr. Johnathan Whetstine & Dr. Jon Chernoff, Fox Chase Cancer Center
9:05–9:35 AM: Peter A. Jones, PhD, DSc (hon), Van Andel Institute
9:35–10:05 AM: Margaret (“Peggy”) Goodell, PhD, Baylor College of Medicine
10:05–10:35 AM: Tony Kouzarides, FMedSci, FRS, University of Cambridge
10:35–11:05 AM: Sharon Y.R. Dent, PhD, The University of Texas MD Anderson Cancer Center
11:05–11:35 AM: Jane Skok, PhD, New York University Grossman School of Medicine
11:35–12:15 PM: MEET THE MORNING SESSION SPEAKERS
12:15–1:00 PM: LUNCH BREAK
1:00–1:30 PM: Cigall Kadoch, PhD, Dana-Farber Cancer Institute & Harvard Medical School
1:30–2:00 PM: Kristian Helin, PhD, Memorial Sloan Kettering Cancer Center
2:00–2:30 PM: Ari M. Melnick, MD, Weill Cornell Medicine
2:30–3:00 PM: Mark Dawson, MBBS (Hons), BMedSci, FRACP, FRCPA, PhD (Cantb), University of Melbourne
3:00–3:30 PM: Cheryl Arrowsmith, PhD, University of Toronto & Princess Margaret Cancer Centre
3:30–4:15 PM: MEET THE AFTERNOON SESSION SPEAKERS
4:15 PM: CLOSING REMARKS & ACKNOWLEDGEMENTS
Sponsors
Special thanks to our symposium sponsors:
|
|
|
